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ABSTRACT 
 
Misexpression of the double homeodomain protein DUX4 in muscle is believed to cause 
facioscapulohumeral muscular dystrophy (FSHD).  Although strategies are being devised 
to inhibit DUX4 activity in FSHD, there is little known about the normal function of this 
protein.  Expression of DUX4 has been reported in pluripotent cells and testis.  To test 
the idea that DUX4 may be involved in initiating a germ lineage program in pluripotent 
cells, we interrogated the effect of DUX4 expression at different stages during in vitro 
differentiation of murine ES cells.  We find that expression of even low levels of DUX4 
is incompatible with pluripotency: DUX4-expressing ES cells downregulate pluripotency 
markers and rapidly differentiate even in the presence of LIF and BMP4.  Transcriptional 
profiling revealed that rather than a germ lineage program, DUX4 induced a 
neurectodermal program.  Embryoid bodies exposed to a pulse of DUX4 expression 
displayed severely inhibited mesodermal differentiation but acquired neurogenic 
potential.  In serum-containing medium in which neurogenic differentiation is minimal, 
DUX4 expression served as a neural inducing factor, enabling the differentiation of 
TuJ1+ neurons.  These data suggest that besides effects in muscle and germ cells, the 
involvement of DUX4 in neurogenesis should be considered as anti-DUX4 therapies are 
developed. 
Introduction 
DUX4 is a double homeodomain protein encoded by a tandem repeat referred to as D4Z4 
[1].  Alterations in repeat number, specifically contractions from the usual approximately 
100 copies down to 10 or fewer cause the dominant genetic disease facioscapulohumeral 
muscular dystrophy (FSHD) [2,3] and many lines of evidence suggest that these 
contractions lead to low-level expression of DUX4, which is normally silent in skeletal 
muscle [4-6].  The homeodomains of DUX4 belong to the paired homeodomain family, 
and within this family are most similar in sequence to PAX3, PAX6, and PAX7.  Pax6 is 
an important regulator of embryonic and adult neurogenesis [7].  Pax3 and Pax7 are key 
determinants of myogenic development [8-10] and muscle satellite cell physiology [11].  
Accordingly, when DUX4 was expressed in myoblasts at low levels, it was found to 
block myotube interfere with myogenic gene expression, block differentiation into 
multinucleated myotubes, and display competitive interactions with both PAX3 and 
PAX7 [12].  Interference with PAX3/7 regulated gene expression pathways governing 
muscle regeneration is thus a likely pathogenic effect of DUX4 expression which may 
explain its involvement in FSHD. 
 
On the other hand, the normal function of DUX4 remains mysterious.  The mouse has a 
homologue named Dux, which is also arrayed in tandem repeats (although fewer in 
number than those of the human) and expressed in various tissues, but most prominently 
in neurogenic tissues [13].  In humans, expression has been reported in testis [6] and a 
role in the expression of germ cell cancer/testis antigens demonstrated [14].  DUX4 
message has also been detected at low levels in human embryonic stem (ES) cells [15]. 
 In order to investigate the role of DUX4 in early development, we created a mouse 
embryonic stem cell (mES) line that would inducibly express DUX4.  The early stages of 
embryo development are well recapitulated in mES cell growth and embryoid body 
differentiation, thus these cells allowed the interrogation of the activity of this 
transcription factor on the development of all of the major lineages.  Although we had 
anticipated that DUX4 might drive germ line differentiation, we found only a very 
modest effect on germ line-specific genes and no evidence of directing pluripotent cells 
into a germ cell fate.  Rather, DUX4 induced a neuroectodermal gene expression program 
at the expense of other major lineage-specific programs, and was able to drive 
neurogenesis in vitro even under non-optimized conditions in which minimal 
neurogenesis normally occurs. 
 
Materials and Methods 
iDUX4 ES cell generation and culture  
The DUX4 ORF was subcloned into p2Lox, the targeting vector for the ICE (inducible 
cassette exchange) recombination system [16]. DUX4 inducible ES cells were generated 
by cassette exchange recombination into the doxycycline-inducible locus upstream of 
HPRT in ZX1 mouse ES cells.  iDUX4 ES cells were cultured on mouse embryonic 
fibroblasts (MEFs) in DME supplemented with 15% FBS, 0.1 mM nonessential amino 
acids (GIBCO), 2 mM glutamax (Invitrogen), penicillin/streptomycin (Gibco), 0.1 mM β-
mercaptoethanol (Sigma), and 1000 U/mL LIF (Millipore), at 37°C in 5% CO2. 
EB differentiation 
ES cells were differentiated as EBs by preplating for 40 minutes to remove MEFs by 
attachment, followed by suspension culture in hanging drops (100 cells per 10μL drop) in 
EBD medium: IMDM (Invitrogen) supplemented with 15% FBS, 200 μg/mL iron-
saturated transferrin (Sigma), 4.5 mM monothiolglycerol (Sigma), 50 μg/mL ascorbic 
acid (Sigma), penicillin/streptomycin (Invitrogen), and 2 mM Glutamax (Invitrogen) at 
37°C in 5% CO2, 5% O2. After 48 hours, EBs were harvested from hanging drops by 
collecting and settling in IMDM.  They were then resuspended in 10mL of EBD and 
plated in non-adherent 10 cm dishes on a swirling rotator (1 rpm).  EBs were fed after 48 
hours by exchanging 50% of spent medium for fresh EBD medium.  Doxycycline 
induction was started at day 2 with the concentrations indicated, and EBs were harvested 
either at day 4 or day 6.  
Growth Curve 
ES cells on MEFs were disassociated with trypsin (Invitrogen) and the MEFs were 
removed by preplating for 40 minutes. 1 × 105 cells were plated on 35mm tissue culture 
dishes in KOSR medium (Gibco) supplemented with 1000 U/ml LIF and10 ng/ml BMP4 
(Peprotech) along with 0, 100, 200 ,300, 400, or 500 ng/ml doxycycline. Every two days 
cells were passaged, cell numbers were counted from triplicate wells of each passage, and 
1 × 105 cells were replated in the same conditions. 
 
Fluorescence-Activated Cell Sorting 
Live cells were gated based on forward scatter (FSC)/side scatter (SSC) profile, and 
negativity for propidium iodine staining to eliminate debris and dead cells. The following 
antibodies were used: c-Kit-allophycocyanin (APC), CD41-phycoerythrin (PE), CD45-
PE, Flk-1-APC, Flk1-PE, platelet-derived growth factor receptor alpha (PDGFRα)-PE, 
PSA-N-cam-APC, (all from eBiosciences). Cells were analyzed and/or sorted on a FACS 
Aria II (BD Biosciences). 
For intracellular Tuj-1 detection, cells were fixed with 1% paraformaldehyde and 
permeabilized with 0.1% TritonX-100. After permeabilization, cells were stained using 
Antibody Diluent with Background-Reducing Components (DAKO).  Cells were 
analyzed as described above, without propidium iodide staining. 
 
qRT-PCR 
RNA was extracted with Ambion RNAqueous® Kit (Life Technologies/Invitrogen); 
reverse transcription was performed with ThermoScript™ Reverse Transcriptase 
(Invitrogen). Quantitative PCR was performed using real-time PCR (7500 or 7900 Real-
Time PCR Systems; Applied Biosystems). In brief, 40 cycles at 95 °C for 12 s and 60 °C 
for 30 s using TaqMan Gene Expression Assay primer-probe sets (Applied Biosystems). 
Quantitative analysis of gene expression was conducted using the comparative cycle 
threshold (Ct) method and means were normalized first to GAPDH then to non-induced 
controls and were compared by t-test.  All PCR reactions were done in triplicate with one 
control reaction containing cDNA that was reverse transcribed without RT enzyme. 
Microarray experiments 
DUX4 was induced with 100 μg/mL doxycycline from EB day 2 and harvested after 48 
of doxycylcine induction. The RNA from three independent replicates of both + dox and 
control was used to generate cRNA probe which was hybridized to MouseWG-6 Bead 
Chip Arrays (Illumina).  Raw data were processed using Beadstudio (Illumina) and 
analyzed using Genespring GX 7.3.1 (Agilent). 
 
RESULTS 
Low-level expression of DUX4 in mES cells downregulates the pluripotent program 
and promotes neuroectodermal gene expression 
Previously we found that high levels of DUX4 expression (from a construct that 
contained the ORF + 1.5 kb of 3’UTR) are toxic to mouse and human myoblast cells and 
that low levels of DUX4 inhibited myogenic differentiation, suggesting a mechanism for 
the involvement of misexpressed FSHD in muscle pathology [12].  We generated a 
doxycycline-inducible DUX4 (iDUX4) mouse ES line (mES) by recombining the DUX4 
ORF into mouse ES cells with an ICE (inducible cassette exchange) locus upstream of 
HPRT [16].  In these ES cells, DUX4 protein expression was visible in the nuclei of cells 
at 24 hours post induction in iDUX4 cells but not in controls (Fig. 1A) and there was a 
direct relationship between the amount of doxycycline added and the amount of DUX4 
RNA (Fig. 1B).  Overexpression of DUX4 at high levels was clearly deleterious and cells 
could not be expanded (Fig 1C; 500 ng/ml).  At low levels, DUX4 was not overtly toxic, 
however these cultures proliferated somewhat more slowly than the controls (Fig. 1C; 
100 ng/ml).  It should be mentioned that DUX4 sensitizes mouse myoblasts to oxidative 
stress, and that acute toxicity can be moderated somewhat by culturing cells wtih 
antioxidants such as beta mercaptoethanol [12], an additive that is present in ES culture 
medium.  Colonies were clearly altered in morphology becoming less refractive with 
flattened separating cells with doxycycline (Fig. 1D). 
 
To determine whether this morphological change indicated a change in pluripotency, we 
induced DUX4 at low levels for 48 hours and evaluated a panel of pluripotent markers 
and differentiation, both by FACs as well as qRT -PCR (Fig.1 E and F).  With the 
exception of Sox2, which was upregulated, all markers of pluripotency, SSEA1, Nanog, 
Klf4, and Oct4 were down regulated with low dose DUX4 induction.  Since DUX4 was 
reported to be expressed in testis and to induce germ cell antigens (among many other 
changes) when expressed in human myoblasts [6,14], we examined germ cell lineage 
markers.  These results were not consistent with the activation of a germ cell program: 
the master regulator, Prdm1 was significantly down regulated; the germ cell marker, Dazl 
was upregulated, while Stella and Vasa showed no change.  Since a primodial germ cell 
linage was not being induced, we evaluated markers of meso-, endo-, and ectoderm.   
Early mesodermal cell fate markers showed no change (Mesp1) or were down regulated 
(Brachyury) while endoderm markers Foxa2 and Sox17 showed no change.  Although 
Sox2 is expressed in pluripotent cells, it is also a key element of the early neurogenic 
program [17,18], so its upregulation might be interpreted as the induction of a neurogenic 
program.  Supporting this idea, all neuroectoderm  markers evaluated (PSA-Ncam, 
Neurog2, and Pax6) were upregulated.  In addition, it should be noted that the epiblast 
marker Fgf5 was upregulated, suggestive of a transition through epiblast to 
neuroectoderm.  
 
DUX4 promotes neuroectodermal differentiation during embryoid body differentiation 
Although the monolayer differentiation study above clearly shows that DUX4 interferes 
with the pluripotent program, monolayer differentiation is not an efficient way to 
generate mesoderm or endoderm.  To test the effect of DUX4 expression on the 
generation of the 3 germ layers, we subjected iDUX4 ES cells to embryoid body (EB) 
differentiation.  During the first two days of EB differentiation, cells progress from the 
ES stage to epiblast.  After this time point, the three germ layers are specified, with the 
earliest germ-layer-specific markers appearing shortly afterwards.  We therefore applied 
100 ng/ml of doxycycline at 48 hours of differentiation and evaluated EBs 48 hours later 
(after 4 days of differentiation).  Under these conditions, doxycycline induction of DUX4 
caused EBs to be somewhat more compact (Fig 2B).  We then performed microarray 
profiling on total EB RNA.  We found no significant differences between treatments for 
most germline-specific or endodermal markers (Fig. 2C).   
 
For genes associated with early mesodermal lineages, results were mixed with some early 
markers upregulated, however this likely reflects lack of appropriate downregulation due 
to impaired differentiation of early specified mesoderm lineage founders as these markers 
normally peak at day 3 and are much lower at day 4.  By this time point, the first wave of 
mesodermal differentiation is well underway, and this first wave prominently produces 
hematopoietic lineage founders while other mesodermal lineages arise slightly later [19].  
Looking at the signature for this first wave, we observed clear downregulation of both 
hematopoietic transcription factors and globins.  Coordinate with this was a decrease in 
most endothelial markers.  However, the most striking signature change was that of the 
neurectoderm and neural genes.  This lineage is typically quite underrepresented in EBs 
grown in serum, however when low levels of DUX4 are induced, almost every marker is 
upregulated.  These results are consistent with DUX4 expression in early development 
inhibiting various mesodermal lineages particularly lateral plate and promoting 
neuroectoderm/neurogenesis. 
 
To support this interpretation, we repeated low dose DUX4 inductions starting at 48 
hours, and interrogated various markers specifically, including surface markers that have 
been associated with specific lineages, and RNA markers by qRTPCR (Fig. 3A). Day 4 
EBs were examined for the early mesoderm markers Flk1 for lateral plate [20], and 
PDGFRa for paraxial mesoderm [21] by FACS analysis (Fig. 3B). In control cultures, 
differentiating EBs developed into Flk1−PDGFRα+ (10.6%), Flk1+PDGFRα+ (34.3%), 
and Flk1+PDGFRα− (9.6%) populations on day 4 of differentiation.  Dox induction 
increased the PDGFRα single-positive population to 44.4%, and decreased Flk1 
expression to negligible levels.  While there was a similar proportion of PDGFRa+ cells 
in treated and control control (45% and 46%), most of these were single positive with dox 
treatment.  Polysialylated neuronal cell adhesion molecule (PSA-NCAM) is expressed in 
early neuronal progenitor cells [22-24] and functions in cell migration [25].  Interestingly 
this protein was expressed with DUX4 induction but almost absent in uninduced EBs.  
Although PDGFRa marks lateral plate mesoderm, it also marks cells which will become 
oligodendrocyte progenitors [26].  The presence of double positive PSA-
NCAM/PDGFRa cells suggests DUX4 is promoting a neuronal cell fate (Fig. 3C).  We 
further explored the induction of neurogenesis by quantitative real-time RT-PCR analyses 
for expression of selected neuroectodermal genes.  Pax6, Neurog2, Gbx-2, Otx-2, Sox2 
and Nestin were all significantly elevated in DUX4-induced EBs.  These results support 
the interpretation that DUX4 promotes early neural progenitors but inhibits mesoderm, 
particularly lateral plate mesoderm. 
 
We performed additional experiments at a later stage of EB development to examine the 
effects of DUX4 on hematopoietic, endothelial, and cardiac progenitors.  DUX4 was 
induced at 100ng/ml from days 2-6 and cells were assayed by FACS and qRTPCR (Fig 4 
B,C).  In accordance with the previous results, we obtained fewer undifferentiated 
hematopoietic progenitors (c-Kit/CD41, c-Kit/CD45), and fewer Flk1/Tie2 or Flk1/CD31 
endothelial cells.   To evaluate cardiogenesis, we analyzed two early cardiac markers 
Nkx2.5, Tbx5 [27] and the terminal marker cardiac troponinT2 (cTnnt2) by qRT-PCR and 
found the expression of all of these markers significantly inhibited by DUX4 induction in 
comparison to uninduced control (Fig. 4C).  These results demonstrate that DUX4 is 
incompatible with the differentiation of the major mesodermal lineages assayable in EBs.   
 
DUX4 promotes neurogenesis 
We wished to follow up on the observation that DUX4 promotes neurectoderm, to see 
whether it could generate differentiated neural cell types under conditions in which few 
such cells are normally formed.  EBs were formed by hanging drops for two days then 
moved to a swirling suspension with doxycycline being added from day 2 through day 6, 
when EBs were allowed to attach to a solid surface and grow for an additional 3 days to 
allow for terminal differentiation (Fig. 5A).  In controls not treated with doxycycline , the 
attached EB gave rise to minimal neurite-like sprouts, while doxycycline induced a 
tremendous number of sprouts.  To quantify this observation, we counted the number of 
number of EBs displaying sprouts.  The DUX4-induced EBs had significantly more 
neurite-like sprouting outgrowths compared to controls (Fig 5B).  These cultures were 
fixed and stained for Tuj-1, which identifies the β-tublin III a structural protein of mature 
neurons.  There was minimal Tuj1 staining in control EBs, but in DUX4-induced EBs, 
Tuj1 was visible throughout the attached colonies, and particularly strongly detected in 
the sprouts, confirming their neuronal identity (Fig 5C).  This differentiation was in the 
absence of conventional neuronal-inducing or -supportive factors like RA, bFGF or 
medium optimized for neuronal differentiation of ES cells.  We also examined cultures in 
which EBs had been trypsinized and cells plated directly on plastic for Tuj1 
immunofluorescence two days later, which also demonstrated TuJ1+ cells (Fig. 5D).  
Finally, we evaluated several neural markers over a time course from days 6 through 9.  
Three terminal neural differentiation markers were examined.  Tuj-1 was dramatically 
upregulated by DUX4 (Fig 5E). There was also significant upregulation of expression of 
two glial genes for terminal differentiation: GFAP, a marker for astrocytes and Olig-2, a 
marker for oligodendrocytes.  These experiments show that DUX4 not only promotes 
neuroectodermal fates, it can induce the formation of neuronal progenitors that are 
capable of terminal differentiation. 
 
Discussion 
The recent correlation of FSHD pathogenesis with the chromosome 4 “permissive” allele 
that contains a signal sequence allowing polyadenylation of DUX4 RNA from the last 
repeat [5], has encouraged researchers to consider using methods to reduce DUX4 RNA 
levels as a therapy for patients [28].  However, it is likely that DUX4 expression has a 
role in normal development because the open reading frame encoding DUX4 is clearly 
under positive selection, ie. if it were not functional and required for something essential, 
it would have acquired mutations that disrupt the ORF [13].  Therefore it is important to 
investigate the normal function of DUX4 before any therapies reducing the level of 
DUX4 in cells should be considered.  For this reason as well as to gain a further 
understanding of the effects of ectopic expression of DUX4 in cells, we have determined 
the effect of expressing DUX4 during ES in vitro differentiation, a powerful system for 
determining the function of genes involved in development.   
Using a dox-inducible promoter to express DUX4 allowed us to titrate down the level of 
expression, to a level at which DUX4 was no longer potently cytotoxic to ES cells 
growing in medium with beta-mercaptoethanol.  Achieving low levels of expression is 
important, as the physiological level of DUX4 expression in primary cells, even in FSHD 
muscle cells, is low [4,6,15,29].  Most previous studies on DUX4 action in cells have 
used overexpression from strong promoters [4,14,30], and there is clearly a high dose-
dependent toxicity of DUX4.  However, very low doses that do not cause overt cell death 
are able to inhibit MyoD expression and block myogenic differentiation of C2C21 cells 
[12], effects that may be more relevant to FSHD than is cell death. 
 
We found that pluripotency was rapidly compromised by low levels of DUX4.  Within 
two days, pluripotent markers were virtually eliminated (SSEA1, Nanog, Oct4 and Klf4).  
This strongly suggests that DUX4 does not play a role in maintaining cells in the 
pluripotent stage.  However, there have been reports of DUX4 RNA expression in WT 
hES and iPS cells [6,15].  We suspect that this may be due not to expression in 
pluripotent cells but to expression in some type of early differentiated cell, of which there 
are always a few in healthy karyotypically normal ES cell cultures.  Because germ cells 
are closely related to ES cells, because DUX4 has been demonstrated to be expressed in 
human testis [6], and because overexpression of DUX4 in human myoblasts induced the 
expression of a selection of germ cell cancer antigens [14], we presumed initially that 
such rare DUX4-expressing cells in hES cultures might be early germ lineage 
progenitors, and therefore that we would find that DUX4 would drive ES cells into the 
germ lineage.  However, we did not see consistent changes in this direction.  The master 
regulator of primordial germ cell development, Prdm1, was downregulated.  One germ 
cell marker, Dazl, was upregulated while others, Vasa and Stella, were unchanged.  The 
clear effect of DUX4 expression in both ES cells and in very early differentiating EBs, 
was the induction of markers indicative of neurogenesis (PSA-Ncam, Sox2, Neurog-2, 
Pax6).  ES cells differentiated in vitro as EBs in serum-containing medium give a 
preponderance of lateral plate mesoderm derivatives [31].  We found that ES cells 
differentiated under these conditions but in the presence of DUX4 induction showed 
severely inhibited lateral plate mesoderm and derivatives (blood and cardiac tissue) but 
had acquired neurogenic potential, even to the point of producing terminally 
differentiated neuronal cells.  These were obtained when a pulse of low level DUX4 
expression was applied during EB differentiation, but then removed as EBs were attached 
to plastic and allowed to differentiate for several more days.  Differentiated TuJ1+ 
neurons were observed by day 11.  It should be emphasized that in these experiments, 
medium was devoid of exogenous retinoic acid, FGF5, or other growth factors and 
cytokines that are usually required for neural induction of ES cells.  In addition, they 
were done in the presence of serum, which is inhibitory to neurogenesis in EBs. 
		
We have previously demonstrated a competitive interaction between DUX4 and Pax3 
/Pax7 for regulation of MyoD and other targets, and proposed that the similarity of the 
homeodomains of DUX4 to those of Pax3 and Pax7 may enable inappropriate interaction 
with Pax3/7 targets in satellite cells which would perturb muscle regeneration [12].  It is 
interesting to note that both Pax3 and Pax7 are expressed in early neural development, 
and that the DUX4 homeodomains are equally similar to those of Pax6, an important 
neurogenic transcription factor.  Based on the molecular similarities therefore, a role for 
DUX4 in neural differentiation is not unreasonable.  Studies of a related gene in mouse, 
Dux, found expression in brain tissues [13].  The particular expression pattern observed 
suggested that mDux might have a role in embryonic development within granule neurons 
and when young mouse brains were examined, expression was observed throughout the 
cortex with localized areas of increased expression.  The experiments presented here 
suggest the importance of looking beyond muscle and germ line function to understand 
DUX4 and that we should consider the possibility that DUX4 has a role in neurogenesis.  
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Figure Legends 
 
FIG. 1. DUX4 perturbs pluripotency and induces neural gene expression. 
(A) DUX4 protein was detected by immunofluorescence in iDUX4 ES with induction 
of 100 ng/ml of doxycycline for 24 hours and not in uninduced control cells.  
DUX4 is localized to the nucleus (left panels) which was made visible by DAPI 
staining and merging of the images (right panels). 
(B) Real time PCR analysis showing the dose responsiveness of DUX4 expression 
from 50 to 300 ng/ml doxycycline for 24 hours.  
(C) Growth curves of iDUX4 ES cells cultured in different concentrations of 
doxycycline.  A dose-dependent inhibition of growth was observed, but this was 
not severe at 100 ng/ml. 
(D) Phase contrast photomicrographs of iDUX4 ES colonies in the presence or 
absence of low dose DUX4 expression. 
(E) FACS analysis of SSEA1 and PSA-NCAM in iDUX4 ES cells induced with 100 
ng/ml doxycycline for 48 hours.  Controls (no doxycycline or no insert) are 
positive for SSEA1 and negative for PSA-NCAM.  Cells induced with 
doxycycline have greatly reduced SSEA1, and demonstrate expression of PSA-
NCAM. 
(F) qRTPCR for markers of pluripotency, germ line, and endo/meso/ecto-derm in 
iDUX4 ES cells induced with doxycycline for 48 hours at 100ng/ml.  Means were 
normalized first to GAPDH then to non-induced controls and were compared by 
t-test with the probability of a larger t value symbolized as p< 0.01 = *,  p< 0.001 
= **, p<0.0001 =***. Scale bars: 100μm in A and D. 
 
FIG. 2. Microarray profiling of day 4 EBs demonstrates neurogenesis. 
(A)  Scheme of differentiation indicating times of induction and analysis. 
(B)  iDUX4 ES cells were aggregated into EBs for 2 days, and induced with 100 
ng/ml doxycycline for 48 hr. while shaking.   
(C) Heat map of lineage-specific markers.  Total RNA from day 4 EBs was used for 
Affymetrix microarray gene chip analysis. Expression levels are compared with 
the median calculated intensity value, as indicated in the scale at the bottom.  
Each heat map box represents an independent biological replicate.   
 
FIG. 3. DUX4 inhibits lateral plate mesoderm and promotes neurectoderm in day 4 
EBs. 
(A) Scheme of differentiation showing dox induction and analysis.  
(B) FACS for Flk-1 and PDGFRa; (C), for PSA-Ncam and PDGFRa; and (D) for 
PSA-NCAM and Flk1 in EBs that were induced with 100ng/ml  doxycyline on days 
2-4 and analyzed on day 4. 
(E) qRTPCR results for day 4 EBs examining neurectodermal markers, Pax6, 
Neurog2, Nestin, Sox2, Gbx-2 and Otx-2.  Means were normalized first to GAPDH 
then to non-induced controls and were compared by t-test with the probability of a 
larger t value symbolized as p< 0.01 = *,  p< 0.001 = **, p<0.0001 =***. 
 
FIG. 4. DUX4 inhibits cardiac and hemangiogenic progenitors in day 6 EBs. 
(A) Scheme of differentiation showing dox induction and analysis. 
(B) FACS expression profiles of EBs that were induced with 100ng/ml doxycyline on 
days 2-6 and analyzed at day 6 for early hematopoietic markers, c-kit and 
CD41/45  or  endothelial markers, Flk1 and Tie-2/CD31. 
(C)  qRTPCR analysis of EBs that were induced with 100ng/ml doxycyline on days 2-
6 and analyzed at day 6 for early cardiac markers, Gata-1, Nkx2.5 and Tbx5.  
Means were normalized first to GAPDH then to non-induced controls and were 
compared by t-test with the probability of a larger t value symbolized as p< 0.01 = 
*,  p< 0.001 = **, p<0.0001 =***.  
 
FIG. 5. DUX4 promotes neuronal differentiation. 
(A) Schematic diagram of differentiation protocol and doxycycline induction.   
(B) Percentage of EBs displaying neurite-sprouting outgrowths. 
(C) Phase contrast image at day 11 of attached and differentiated EBs (left panel) and 
enlarged images (second panel) with or without 100 ng/ml doxycycline induction 
as shown in (B). Immunostaining for Tuj1 (third panel from left) and merged with 
the DAPI-stained images (right panel) in attached EBs.   
(D) Immunostaining for Tuj1 (left) and merged with the DAPI-stained images (right) 
after cells from day 9 EBs were dissociated with trypsin and replated onto gelatin-
coated dishes for 2 days. 
(E) Three terminal neural differentiation markers (GFAP, Olig-2 and Tuj1) were 
examined by qRT-PCR.  Means were normalized first to GAPDH then to non-
induced day 6 controls and were compared by t-test with the probability of a 
larger t value symbolized as p< 0.01 = *, p< 0.001 = **, p<0.0001 =***. Scale 
bars: 500μm in phase contrast and 400μm immunofluorescence in B and 200μm 
in D. 
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